Is PT-141 (Bremelanotide) Legal in Washington State?
HealthRX.com
No Washington-specific rule found for PT-141
See the public record for Bremelanotide
At a glance
- Federal status / Prescription-only; FDA-approved as Vyleesi, June 21, 2019 [1][2]
- Approved use / Premenopausal women with acquired, generalized HSDD [1]
- Not indicated for / Men, postmenopausal women, or enhancing sexual performance [1]
- Washington-specific rule / None found
- FDA bulk-substance lists / Bremelanotide in no category [4][5]
- Approved dose / 1.75 mg subcutaneous, at least 45 minutes before activity [1]
- Contraindications / Uncontrolled hypertension or known cardiovascular disease [1]
What federal law says about bremelanotide
Vyleesi is the FDA-approved bremelanotide product. Its approval (NDA 210557) dates to June 21, 2019, and the application is now held by Cosette Pharmaceuticals, which took it over from AMAG [1][2]. It is a 1.75 mg subcutaneous injection in a prefilled autoinjector and is prescription-only [1].
The approved use is narrow: premenopausal women with acquired, generalized HSDD, meaning low desire causing marked distress or interpersonal difficulty that is not due to a medical or psychiatric condition, relationship problems, or a medication or drug. The label says it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].
Washington State
We found no Washington-specific rule on bremelanotide. The established position is federal and applies nationwide: Vyleesi is an FDA-approved, prescription-only drug [1][2].
Questions worth asking
'PT-141' sold as a peptide is a different product
Compounded bremelanotide and PT-141 sold for research use are not Vyleesi and are not FDA-approved drugs. Compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before marketing [3][1].
Bremelanotide does not appear on FDA's list of bulk substances that may present significant safety risks (page content dated April 22, 2026) [4], it is not in any category on FDA's bulk-substance lists [5], and it is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [6].
Prescription PT-141 information is available at PT-141.
What the label says about using it
The labeled dose is 1.75 mg under the skin of the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. The label says not to give more than one dose within 24 hours, that more than 8 doses per month is not recommended, and to stop after 8 weeks if symptoms have not improved [1].
Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease and is not recommended in patients at high risk for cardiovascular disease [1]. Each dose briefly raises blood pressure: the maximal increases in clinical studies were 6 mmHg systolic and 3 mmHg diastolic, while an ambulatory study of 127 premenopausal women dosed once daily for 8 days found mean daytime increases of 1.9 and 1.7 mmHg [1].
Athletes
Bremelanotide is not named on WADA's 2026 Prohibited List. Because bremelanotide is FDA-approved as Vyleesi, WADA's S0 class for substances with no approval from any governmental health authority does not apply by definition [1][7].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is PT-141 legal in Washington State?
Is PT-141 FDA-approved?
Is compounded or research-use PT-141 the same as Vyleesi?
What is the approved dose?
References
Show all 7 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.